, China
Photo from Envato

China emerges as key player in oncology with antibody-drug conjugates surge

It represents 82% of the ADC pipeline in major APAC markets.

A surge in antibody-drug conjugates (ADCs) is driving China to position itself as a key player in the oncology sector, according to GlobalData.

Of the 124 ADCs currently in development across Australia, Japan, and South Korea, China accounts for 102, representing 82% of the pipeline in major Asia Pacific markets.

Two ADCs were domestically developed amongst the eight approved in the country, namely Licartin for liver cancer and disitamab vedotin (Aidexi) for gastric cancer and urothelial cell carcinoma.

Meanwhile, 46 companies are engaged in developing ADC drugs across Phases I to III.

Moreover, strategic partnerships between key pharmaceutical companies and Chinese firms have surged in the past five years. A notable deal occurred in 2021 between Seagen Inc., now part of Pfizer Inc., and RemeGen, valued at $2.6b for the ADC Aidexi.

According to Nelluri Geetha, a Pharma Analyst at GlobalData, cancer is currently the leading cause of death in China and is expected to rise further.

“ADCs have become a focal point in oncology due to their ability to selectively target cancer cells, resulting in reduced off-target side effects,” Geetha said.

 

Follow the links for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Exclusives

Saudi’s KFSHRC banks on innovation to transform healthcare
The hospital is accelerating adoption of emerging technologies to position itself as a global leader in medicine
Angkor Hospital eyes trauma centre for children
The facility will have an ICU, emergency room, operating theatre and a surgical ward.